Kirtland Hills Capital Management LLC Acquires 39 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Kirtland Hills Capital Management LLC grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 2,219 shares of the medical research company’s stock after purchasing an additional 39 shares during the period. Kirtland Hills Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $1,155,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of TMO. FMR LLC increased its stake in shares of Thermo Fisher Scientific by 19.7% in the 3rd quarter. FMR LLC now owns 7,877,459 shares of the medical research company’s stock valued at $4,872,761,000 after purchasing an additional 1,294,453 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in shares of Thermo Fisher Scientific during the 3rd quarter valued at $254,412,000. Lindsell Train Ltd acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at $211,858,000. Franklin Resources Inc. boosted its holdings in shares of Thermo Fisher Scientific by 5.7% during the 3rd quarter. Franklin Resources Inc. now owns 4,853,133 shares of the medical research company’s stock valued at $2,935,377,000 after acquiring an additional 262,062 shares in the last quarter. Finally, National Bank of Canada FI boosted its holdings in shares of Thermo Fisher Scientific by 66.9% during the 3rd quarter. National Bank of Canada FI now owns 646,692 shares of the medical research company’s stock valued at $400,024,000 after acquiring an additional 259,123 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on TMO. Morgan Stanley raised their price objective on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a report on Friday, January 31st. Scotiabank raised their price objective on Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a “sector perform” rating in a report on Monday, February 3rd. Raymond James reaffirmed an “outperform” rating and set a $667.00 target price (up from $650.00) on shares of Thermo Fisher Scientific in a report on Monday, February 3rd. UBS Group lifted their target price on Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a “buy” rating in a report on Friday, January 31st. Finally, Bank of America cut their target price on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Four research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average target price of $656.86.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $539.86 on Wednesday. Thermo Fisher Scientific Inc. has a one year low of $493.30 and a one year high of $627.88. The firm has a market capitalization of $206.50 billion, a price-to-earnings ratio of 32.66, a PEG ratio of 2.99 and a beta of 0.77. The business has a 50-day simple moving average of $548.80 and a 200 day simple moving average of $566.46. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, beating analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be issued a dividend of $0.43 per share. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a yield of 0.32%. The ex-dividend date of this dividend is Friday, March 14th. Thermo Fisher Scientific’s payout ratio is currently 10.41%.

Thermo Fisher Scientific declared that its board has initiated a stock repurchase plan on Friday, November 15th that allows the company to repurchase $4.00 billion in shares. This repurchase authorization allows the medical research company to repurchase up to 2% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s leadership believes its stock is undervalued.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $175,677.00. Following the completion of the sale, the executive vice president now directly owns 16,363 shares of the company’s stock, valued at approximately $9,582,009.17. The trade was a 1.80 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Stephen Williamson sold 9,825 shares of the business’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the sale, the chief financial officer now directly owns 27,296 shares of the company’s stock, valued at $15,984,264.64. This represents a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 20,125 shares of company stock valued at $11,231,699. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.